High seroprevalence of Leishmania infantum is linked to immune activation in

2 people with HIV: a two-stage cross-sectional study in Bahia, Brazil

1

3

12

- 4 Laise de Moraes^{1,2}, Luciane Amorim Santos^{1,2,3}, Liã Bárbara Arruda⁴, Maria da
- 5 Purificação Pereira da Silva⁵, Márcio de Oliveira Silva⁵, José Adriano Góes Silva^{1,2,5},
- 6 André Ramos⁵, Marcos Bastos dos Santos², Felipe Guimarães Torres², Cibele Orge²,
- 7 Antonio Marcos Teixeira², Thiago Vieira², Laura Ramírez⁶, Manuel Soto⁶, Maria
- 8 Fernanda Rios Grassi^{2,3}, Isadora Cristina de Siqueira², Dorcas Lamounier Costa⁷, Carlos
- 9 Henrique Costa⁷, Bruno de Bezerril Andrade^{2,3}, Kevan Akrami^{1,2}, Camila Indiani de
- Oliveira^{1,2,3}, Viviane Sampaio Boaventura^{1,2,8}, Manoel Barral-Netto^{1,2}, Aldina Barral^{1,2*},
- 11 Anne-Mieke Vandamme^{9*}, Johan Van Weyenbergh^{9*}, Ricardo Khouri^{1,2,9}
- 13 1 Programa de Pós-graduação em Ciências da Saúde, Faculdade de Medicina da Bahia,
- 14 Universidade Federal da Bahia, Salvador, Brazil.
- 15 2 Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Brazil.
- 16 3 Escola Bahiana de Medicina e Saúde Pública, Salvador, Brazil.
- 4 Centre for Clinical Microbiology, Division of Infection & Immunity, University
- 18 College London, London, United Kingdom.
- 19 5 Centro Estadual Especializado em Diagnóstico, Assistência e Pesquisa, Secretaria de
- 20 Saúde do Estado da Bahia, Salvador, Brazil.
- 21 6 Departamento de Biología Molecular, Facultad de Ciencias, Centro de Biología
- 22 Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad
- 23 Autónoma de Madrid, Madrid, Spain.
- 24 7 Laboratório de Leishmanioses, Instituto de Doenças Tropicais Natan Portella,
- 25 Universidade Federal do Piauí, Teresina, Brazil.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 8 Hospital Santa Izabel, Salvador, Brazil.
- 9 Department of Microbiology, Immunology and Transplantation, Rega Institute for
- 28 Medical Research, Clinical and Epidemiological Virology, KU Leuven, Leuven,
- 29 Belgium.

32

- 31 *equal contribution
- 33 **Short title:** *Leishmania* seropositivity linked to immune activation in people with HIV

ABSTRACT

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

Background: Visceral leishmaniasis is an opportunistic disease in HIV-1 infected individuals, although not yet recognized as a determining factor for AIDS diagnosis. The growing geographical overlap of HIV-1 and *Leishmania* infections is an emerging challenge worldwide, as co-infection increases morbidity and mortality for both. Here, we determined the prevalence of people living with HIV (PWH) with a previous or ongoing infection by *Leishmania infantum* in Bahia, Brazil and investigated the virological and immunological factors associated with co-infection.

Methodology and Principal Findings: We adopted a two-stage cross-sectional cohort (CSC) design (CSC-I, n=5,346 and CSC-II, n=317) of treatment-naïve HIV-1-infected individuals in Bahia, Brazil. In CSC-I, samples collected at the time of HIV-1 diagnosis between 1998 and 2013 were used for serological screening for leishmaniasis by an inhouse immunoassay (ELISA) with SLA (Soluble Leishmania Antigen), resulting in a prevalence of previous or ongoing infection of 16.27%. Next, 317 PWH were prospectively recruited from July 2014 to December 2015 with collection of sociodemographic and clinical data. Serological validation by two different immunoassays confirmed a prevalence of 15.46% and 8.20% by anti-SLA, and anti-HSP70 serology, respectively, whereas 4.73% were double-positive (DP). Stratification of these 317 individuals in DP and double-negative (DN) revealed a significant reduction of CD4+ counts and CD4+/CD8+ ratios and a tendency of increased viral load in the DP group, as compared to DN. No statistical differences in HIV-1 subtype distribution were observed between the two groups. However, we found a significant increase of CXCL10/IP-10 (p=0.0076) and a tendency of increased CXCL9/MIG (p=0.061) in individuals with DP serology for L. infantum, demonstrating intensified immune

activation in this group. These findings were corroborated at the transcriptome level in independent *Leishmania*- and HIV-1-infected cohorts (Swiss HIV Cohort and Piaui Northeast Brazil Cohort), indicating that *CXCL10* transcripts are shared by the IFN-dominated immune activation gene signatures of both pathogens and positively correlated to viral load in untreated PWH.

Conclusions/Significance: This study demonstrated a high prevalence of PWH with *L. infantum* seropositivity in Bahia, Brazil, linked to IFN-mediated immune activation and a significant decrease in CD4⁺ levels. Our results highlight the urgent need to increase awareness and define public health strategies for the management and prevention of HIV-1 and *L. infantum* co-infection.

AUTHOR SUMMARY

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

More than 1 billion people live in areas endemic for leishmaniasis and are at risk of infection, which includes one third of the 38 million people living with HIV (PWH) worldwide. Leishmaniasis is a neglected tropical disease caused by infection with Leishmania parasites, transmitted by bites from infected sand flies. HIV/Leishmania coinfection is increasing worldwide, especially in Southern Europe and Brazil, due to both human and ecological factors (migration, climate change, deforestation). This study demonstrates that a worryingly high number (one out of 6) of PWH in Bahia (Northeast Brazil) show previous or ongoing infection with the parasite Leishmania infantum, determined by antibodies detection against this parasite in PWH. Using a rigorous study design with data collection over 18 years in >5500 PWH, we found similarly high numbers (16.3% and 15.5%) of PWH with antibodies against *Leishmania infantum* in two consecutive cohorts. Moreover, PWH with antibodies against Leishmania infantum in Bahia, Brazil displayed a worse immune profile, with lower CD4 immune cells numbers and immune activation mediated by interferon, which we confirmed in independent HIVand Leishmania-infected cohorts from other geographic areas. Our results underscore the need to raise awareness and define public health strategies to prevent HIV/Leishmania co-infection, since therapeutic failure and mortality are strongly increased in co-infected PWH, even with antiretroviral therapy as standard of care.

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

INTRODUCTION HIV is the etiological agent of Acquired Immunodeficiency Syndrome (AIDS), a slowly progressive disease characterized by chronic immune activation resulting from the loss of cell-mediated immune function [1,2]. Host genetic factors (e. g. HLA genotypes) and host immune response (e.g. release of proinflammatory cytokines and chemokines), as well as the presence of co-infections, can directly influence the rate of disease progression [2-4].Neglected Tropical Diseases (NTDs) are endemic among the most impoverished populations in Africa, Asia and Latin America. Among these NTDs, visceral leishmaniasis (VL), caused by infection with Leishmania infantum, is associated with increased morbidity and mortality in people with HIV-1 (PWH) but has not been recognized as a diagnostic criterion for AIDS [5]. The World Health Organization (WHO) identified the geographical overlap of both infections as an emerging challenge in successfully controlling the HIV-1 infection in countries considered endemic for leishmaniasis, such as Brazil [6]. The few studies evaluating the prevalence of HIV-1 and L. infantum coinfection on a national level in Brazil [7,8] have highlighted regions endemic for leishmaniasis: Distrito Federal [9], Ceará [10,11], Maranhão [12,13], Mato Grosso [14], Mato Grosso do Sul [15,16], Minas Gerais [17,18], Pernambuco [19], Piauí [20], Rio Grande do Norte [21,22], Sergipe [23] and Tocantins [24]. Bahia is also considered an endemic area for leishmaniasis, with an incidence rate of 0.08/10.000 inhabitants for VL reported in 2018 [25]. In addition, the increase of geographical overlap between HIV-1 and *Leishmania* infection in Bahia [25,26] has raised public health concerns. However, no

115 epidemiological studies have attempted to investigate the prevalence of co-infection to 116 date. Therefore, we investigated the seroprevalence of L. infantum in PWH in the state of 117 Bahia, Brazil and attempted to identify virological and immunological factors associated 118 with co-infection, supported by publicly available transcriptomic data.

METHODOLOGY

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

Study population and design

A two-stage cross-sectional cohort study (CSC-I, 1998-2013 and CSC-II, 2014-2015) was designed to determine the seroprevalence of L. infantum in PWH and to evaluate the association with demographic, clinical, virological and immunological parameters (Figure 1). From 1998 to 2015, individuals with a new confirmed diagnosis of HIV-1 at the Specialized Center for Diagnosis, Care and Research (CEDAP), a state government public health reference service located in the city of Salvador, Bahia-Brazil, were included in this study. Their remaining blood sample was utilized for the outlined assays herein. First, serological reactivity to L. infantum was assessed in plasma or serum samples from the retrospective cross-sectional cohort (n=5,346) collected between 1998 and 2013. In the second stage, serological reactivity to L. infantum was assessed in a prospective cross-sectional cohort of 317 PWH (sampled between July 2014 and December 2015), with demographic and clinical data (sex, age, HIV-1 viral load, CD4⁺, CD8⁺, CD4/CD8 ratio and CD45⁺ T cell counts) prospectively obtained from the clinical records. Additionally, we performed a subpopulation analysis on a subset of PWH identified as either double-positive or double-negative using two independent anti-Leishmania immunoassays. Based on these stringently defined categories, we compared virological and immunological factors influenced by L. infantum seropositivity. The study's recruitment did not interfere with standard medical care, and patients were treated according to the general Brazilian/WHO guidelines. This study was conducted following the Declaration of Helsinki and was approved by the Institutional Review Board of the Gonçalo Moniz Institute (IGM-FIOCRUZ) (protocol number 1.764.505).

141

perpetuity.

It is made available under a CC-BY 4.0 International license.




Figure 1. Flow chart of study design detailing the two-stage cross-sectional and prospective cohort study among people living with HIV in Bahia, Brazil.

Detection of anti-Leishmania and anti-Trypanosoma antibodies

All samples underwent a previously described and validated in-house enzyme-linked immunosorbent assay (ELISA) for the detection of IgG against Soluble *Leishmania infantum* Antigen (SLA), which we previously demonstrated as a sensitive biomarker (90% sensitivity and 95% specificity) of current or past infection with the parasite [27]. SLA preparation and ELISA procedures were performed as previously described [28]. For the prospective cohort of 317 samples from PWH with digitalized clinical records, results of the SLA immunoassay were compared with a second, previously described ELISA employing recombinant *L. infantum* heat shock protein 70 (HSP70), for which we once found a sensitivity of 74% and a specificity of 73% [29]. To avoid false-positive results for *L. infantum* due to cross-reactivity among Trypanosomatidae parasites, an ELISA for anti-*Trypanosoma cruzi* IgG (Euroimmun) was employed in a subset of 42

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

samples with dual-positive (DP) (n=15) and double-negative (n=27) serology for anti-SLA and anti-HSP70. Control samples and ELISA cutoff value Positive (n=6) Leishmania-infected patient samples and negative (n=47) control samples previously identified by the intradermal Leishmanin (also known as Montenegro) Delayed-type Hypersensitivity (DTH) skin test, with clinical and laboratorial confirmation, were used to establish anti-SLA and anti-HSP70 ELISA cutoff values. For each assay, specific cutoff values were determined using the mean OD values obtained from the included negative samples plus three times the observed standard deviation, with each assay's index values corresponding to the OD/cutoff ratio (Supplementary Figure 1). Quantification of immunological markers A Cytometric Bead Array (CBA) Human Inflammatory Cytokines Kit (BD Biosciences) was employed to quantify plasma concentrations of IL-1β, IL-6, IL-10, IL-12p70 and TNF, while CCL2/MPC-1, CCL5/RANTES, CXCL8/IL-8, CXCL9/MIG CXCL10/IP-10 quantification was performed using a CBA Human Chemokine Kit (BD Biosciences), each following the manufacturer's instructions. Data acquisition and analysis were performed using a FACSArray Bioanalyzer (BD Biosciences) and FlowJo v.10.0.5 (Tree Star) software, respectively. **HIV-1 sequencing analyses** Viral RNA isolation was performed using a OIAamp Viral RNA Mini Kit (OIAGEN) following the manufacturer's instructions. The protease/reverse transcriptase (PR/RT) region was amplified and sequenced as previously described [30]. Outer polymerase

184 chain reaction (PCR) was performed using a SuperScript III One-Step RT-PCR System 185 with Platinum Tag DNA Polymerase (Thermo Fisher Scientific) and the following 186 **K**1 (CAGAGCCAACAGCCCCACC) primers: K2 and 187 (TTTCCCCACTAACTTCTGTATGTCATTGACA) [31]. Inner PCR was performed 188 using Platinum Taq DNA Polymerase High Fidelity (Thermo Fisher Scientific) with the 189 following primers: DP16 (CCTCAAATCACTCTTTGGCAAC) RT4 190 (AGTTCATAACCCATCCAAAG) [32]. The generated inner PCR products were 191 sequenced using a BigDye Terminator v.3.1 Cycle Sequencing Kit (Applied Biosystems) 192 with capillary electrophoresis run on an ABI 3500xL Genetic Analyzer (Applied 193 Biosystems) employing the following primers: F1 (GTTGACTCAGATTGGTTGCAC), 194 F2 (GTATGTCATTGACAGTCCAGC) [33],DP10 195 (CAACTCCCTCTCAGAAGCAGGAGCCG), DP11 196 (CCATTCCTGGCTTTAATTTTACTGGTA) [34],RT4 197 (AGTTCATAACCCATCCAAAG), GABO1 (CTCARGACTTYTGGGAAGTTC) and 198 GABO2 (GCATCHCCCACATCYAGTACTG) [30]. Sequence visualization, editing 199 and assembly were performed using Geneious v.10.0.8 (Biomatters) software. HIV-1 200 subtyping was determined using the REGA HIV-1 Subtyping Tool v.3.4.1 201 (https://www.genomedetective.com/app/typingtool/hiv) and the jpHMM-HIV approach 202 [35]. Phylogenetic analysis was conducted using HIV-1 subtype references retrieved from 203 the Los Alamos HIV database sequence 204 (https://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html) (Supplementary 205 Table 1). Phylogenetic inference was performed using PhyML v.3.0 [36], applying the 206 BIONJ method and using the General Time Reversible (GTR) nucleotide substitution 207 model with 1,000 bootstrap replicates.

Transcriptome and systems biology analysis

Transcriptome analysis of publicly available data was performed as recently described [37–39]. Overlap ratio was calculated as: k/K= # Genes in Overlap (k) / # Genes in Gene Set (K) using Molecular Signatures Database (MSigDb). HIV-1 (Swiss HIV Cohort, n=137) [40] and *Leishmania*-infected individuals (Piaui Northeast Brazil Cohort, n=30) [41] were analyzed using GEO2R from Gene Expression Omnibus (GEO).

Statistical analysis

Since data were not normally distributed, as identified by the Shapiro-Wilk and D'Agostino-Pearson tests (GraphPad Prism v.7.0), results were analyzed using non-parametric tests: Mann-Whitney test and Spearman's correlation, as well as Fisher's exact

test, with p<0.05 considered statistically significant.

222

223

224

225

226

227

228

229

230

231

232

233

234

235


236

237

238

239

RESULTS Detection of IgG antibodies against Leishmania (L.) infantum antigens (anti-SLA and anti-HSP70) in people living with HIV (PWH) To determine the seroprevalence to L. infantum among PWHs, 5,346 plasma or serum samples from treatment-näive HIV-1-infected individuals diagnosed between 1998 and 2013 were tested for the presence of IgG antibodies against soluble L. infantum antigen (anti-SLA) (Figure 1). Positivity for anti-SLA serology was detected in 870/5,346 samples, resulting in an prevalence rate of 16.27% (Figure 2). Samples from patients with clinically confirmed diagnosis of visceral leishmaniasis (VL) and laboratory-confirmed L. infantum infection in the absence (n=16) or presence of HIV-1 co-infection (n=10) were used as an additional control [42]. As shown in Figure 2A, anti-SLA antibodies were detected in 81.25% and 100% of HIV-1-negative and HIV-1-positive VL patients, respectively. Besides, we found humoral immune response against SLA in VL patients quantitatively similar regardless of the presence of HIV-1 co-infection (Mann Whitney p=0.71, HIV-negative vs HIV-positive). Thus, we could confirm the high specificity of the L. infantum anti-SLA IgG serology protocol employed herein.






Figure 2. Detection of anti-*L. infantum* **IgG antibodies in plasma/serum samples collected from PWH between 1998 and 2013.** A) Violin plot with a dot-plot overlay of OD index values representative of *L. infantum* anti-SLA serology in the retrospective PWH cohort (n=5,346) and a clinical- and laboratory-confirmed control group (HIV-1-VL+, n=16; and HIV-1-VL+, n=10). Filled black circles (●): PWH cross-sectional cohort

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

samples; filled red circles (•): clinical HIV-1 negative controls with VL; filled red squares with black borders (•): clinical controls with HIV-1 positive controls and VL. B) Pie chart representation of samples (expressed as percentages) with positive (red) and negative (gray) anti-SLA *L. infantum* serology. Subsequently, to validate our findings, we enrolled an independent prospective CSC between 2014 and 2015, composed of 317 treatment-näive HIV-1-infected individuals from which complete demographic and clinical data were obtained from digitalized clinical records. Moreover, we combined anti-SLA serology with a second specific assay to detect IgG antibodies against L. infantum HSP70 recombinant protein (anti-HSP70) (Figure 1). The overall prevalence of anti-SLA positive serology in the prospective cohort was 15.46% (49/317), similar to the cross-sectional cohort results. The prevalence of anti-HSP70 positive serology in the prospective cohort was 8.20% (26/317) (Figure 3). Positivity for both anti-SLA and anti-HSP70 (i.e., double-positivity – DP) was detected in 4.73% (15/317) of the cohort; anti-SLA positive serology alone was detected in 10.73% (34/317); anti-HSP70 serology alone in only 3.47% (11/317) and the union of both anti-SLA and anti HSP70 positive serology was detected in 18.93% (Figure 3D).




Figure 3. Detection of anti-L. infantum IgG antibodies in plasma samples collected from PWH between 2014 and 2015. A) Violin plot with a dot-plot overlay of OD index values representative of L. infantum anti-SLA and anti-HSP70 serology in the PWH prospective cohort (n=317). The red symbols represent the DP individual diagnosed with visceral leishmaniasis >20 years ago. B-C) Pie chart representation (expressed as percentages) of samples positive for B) L. infantum anti-HSP70 (blue) and C) L. infantum anti-SLA (red). Percentages of negative samples are depicted in gray. D) Venn diagram illustrating overlap in detection between L. infantum anti-SLA and anti-HSP70 serological methods.

267

268

269

270

271

272

273

274

275

276

277

Based on these findings, DP (n=15) was adopted as the most stringent criterium for L. infantum infection. Assessment of standard diagnosis of previous or ongoing visceral leishmaniasis (VL) documented in the clinical records showed that one of the 15 DP subjects had VL reported >20 years ago (anti-SLA index=4.71; anti-HSP70 index=2.67). After two decades of clinical diagnosis, this pronounced humoral response most likely reflects chronic antigen exposure, supporting the concept that Leishmania infection is lifelong in most patients as observed in murine models of disease [43–45]. These results, taken together, demonstrated that a significant number of PWH in the state of Bahia are unaware of their exposure to and/or infection by L. infantum and are at risk of developing new or relapsing visceral leishmaniasis.

Demographic and clinical markers associated with dual-positive L. infantum

serology in PWH

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

The CSC-II (n=317) consisted of predominantly young males (72.23%) with a median age of 32 years old at the time of HIV diagnosis, median viral load of 40,370 copies/mL (IQR=7,032-141,359), CD4⁺ T cell count of 369 cells/μL (IQR=163-609), CD8⁺ T cell count of 1,025 cells/µL (IQR=715-1,441), and CD45⁺ T cell count of 2,144 cells/µL (IQR=1,507-2,763) (Table 1).

Table 1. Epidemiological, virological and immunological characteristics of PWH in Bahia (Brazil) between 2014 and 2105, stratified according to DP and DN_{total}

Data are expressed as median values, interquartile ranges (IIO) and numbers of individuals evaluated (N), or as proportions (%) with the number of individuals evaluated in parentheses. The Mann-Whitney test was used to determine statistical differences between DP and DN_{total}; p values considered statistically significant (p<0.05) are shown in bold. DP: dual-positive; DN_{total}: total double-negative; NA: not analyzed

	n=317	DP (n=15)	DN _{total} (n=257)	p value
Male, n	72.23% (229)	73.33% (11)	70.42% (181)	NA

Age, years	32 (26-41)	41 (30-50)	32 (25-39)	0.0430
HIV-1 viral load, copies/mL	40,370 (7,032-141,359)	64,746 (2,480-532,702)	34,956 (6,330-127,747)	0.1268
$CD4^{\scriptscriptstyle +}T\;cell\;count,cell/\mu L$	369 (163-609)	168 (107-449)	405 (188-641)	0.0208
$CD8^+T\;cell\;count,cell/\mu L$	1,025 (715-1,441)	950 (688-1,546)	1025 (728-1,443)	0.8679
CD4 ⁺ /CD8 ⁺ T cell ratio	0.33 (0.14-0.59)	0.21 (0.060-0.37)	0.35 (0.15-0.63)	0.0282
$CD45^{\scriptscriptstyle +} \ T \ cell \ count, \ cell/\mu L$	2,144 (1,507-2,763)	1,758 (1,142-3,028)	2,198 (1,585-2,793)	0.3262

Comparative analyses between the DP (n=15) and total double-negative (DN_{total}) (n=257) groups indicated that individuals with antibodies against both SLA and HSP70 L. *infantum* were older (p=0.0430), presented lower baseline CD4⁺ T cell counts (p=0.0208) and lower CD4⁺/CD8⁺ T cell ratios (p=0.0282), as well as a tendency towards higher HIV-1 viral load levels (p=0.1268) suggestive of an advanced stage of HIV-1 infection than individuals without L. *infantum* antibodies (Table 1). Indeed, a large proportion of DP individuals (10/15, 66.67%) had <200 CD4+ T cells/ μ L at the time of HIV-1 diagnosis, which is considered AIDS-defining.

Subpopulation analysis reveals virological and immunological markers associated

with dual-positive L. infantum serology in PWH

To ensure specificity for *L. infantum* in the DP serological samples and to exclude the possibility of cross-reactivity due to polyclonal activation and hypergammaglobulinemia, anti-*Trypanosoma cruzi* IgG serology was performed. Samples demonstrating positivity for anti-*T. cruzi* IgG (n=2) were excluded from subsequent analyses (Supplementary Figure 2). Next, we performed a subpopulation analysis by matching DN individuals to the DP group by gender, age, viral load and CD4⁺ T cell count. This strategy resulted in the establishment of a third group (DN_{paired}) (Figure 1), thereby mitigating the possibility of bias arising from polyclonal activation, hypergammaglobulinemia, high viral load or low CD4⁺ T cell levels. Controlling for these parameters limited the potential for

variations in the HIV-1 transcriptomic profile and the state of immune activation. No statistical differences were observed between the DP and DN_{paired} groups regarding sociodemographic and clinical parameters, which underscores the pairing strategy's equity (Table 2).

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

Table 2. Epidemiological, virological and immunological characteristics of PWH in Bahia (Brazil) between 2014 and 2105, stratified according to DP and DN_{paired}. Data are expressed as median values, interquartile ranges (IIQ) and numbers of individuals evaluated (N), or as proportions (%) with the number of individuals evaluated in parentheses. The Mann-Whitney test was used to determine statistical differences between DP and DN_{paired}; p values considered statistically significant (p<0.05) are shown in bold. DP: dual-positive; DN_{paired}: total double-negative; NA: not analyzed

	DP (n=14)	DN _{paired} (n=26)	p value
Male, n	78.57% (11)	88.46% (23)	NA
Age, years	42 (29-51)	33 (26-43)	0.2224
HIV-1 viral load, copies/ml	147,580 (2,284-700,074)	76,298 (15,757-141,159)	0.4572
CD4+ T cell count, cell/μl	166 (91-450)	300 (128-472)	0.4113
CD8+ T cell count, cell/μl	1,008 (744-1,607)	995 (852-1,489)	0.7474
CD4+/CD8+ T cell ratio	0.21 (0.058-0.39)	0.29 (0.14-0.49)	0.3954
CD45+ T cell count, cell/µl	1,788 (1,262-3,054)	1,958 (1,628-2,585)	0.6641

To investigate possible associations between transmission clusters of a more-aggressive HIV subtype and worsen HIV clinical status, HIV-1 subtyping was performed in the DP and DN_{paired} subset to infer. After excluding samples with a viral load <1,000 copies/mL, both groups were pooled together (n=19) and submitted to phylogenetic analysis using the jpHMM-HIV model (Supplementary Figure 3). Concerning subtype distribution,

342

343

344

345

346

347

348

349

350

351

352

353

354


355

356

357

358


subtype B (63.16%, 12/19) was the most prevalent, followed by subtypes C (15.79%, 3/19), recombinant BF (15.79%, 3/19) and D (5.26%, 1/19). No statistical differences in subtype were observed between the DP and DN_{paired} groups (p=0.67) (Supplementary Table 2). No transmission cluster was identified. HIV-1 subtyping showed no impact on L. infantum serology titers, viral load, T cell count, or any other host immunological marker evaluated, indicating that HIV-1 subtypes B, C, D, F1 and BF exhibit similar virological and immunological outcome in HIV/L. infantum co-infection. Next, we quantified circulating cytokines and chemokines that might reflect an increase in systemic immune activation and have been previously associated with infection to L. infantum [46–49]. The systemic levels of cytokines tested (IL-1\beta, IL-6, IL-10, IL-12p70) and TNF) were below the detection limits in all samples (DP and DN_{paired} groups), concordant with our previous findings in a large Cuban cohort of PWH [4]. Conversely, most chemokines (except IL-8) were readily detected in most PWH, demonstrating a significant increase in CXCL10/IP-10 (p=0.0076) and a tendency towards higher CXCL9/MIG levels (p=0.061) (Figure 4) in the DP group compared to DN_{paired}, suggesting increased immune activation in the group with DP serology for L. infantum.



Pigure 4. Chemokine profiles obtained from plasma/serum samples of DP and DN_{paired} groups. A-E) Violin plots with dot-plot overlays illustrating chemokine plasma levels (pg/mL). Statistical comparisons made by the Mann-Whitney test in plasma levels (pg/mL) of CCL2/MPC-1 (p=0.43), CCL5/RANTES (p=0.94), CXCL8/IL-8 (p=0.54), CXCL9/MIG (p=0.061) and CXCL10/IP-10 (p=0.0076) chemokines. Open squares (□): subgroup of double-positive PWH (positive for both anti-SLA and anti-HSP70 *L. infantum* antigens); open circle (○): subgroup of paired double-negative PWH (serologically negative for anti-SLA and anti-HSP70 *L. infantum* antigens). The red

symbol represents the DP individual diagnosed with visceral leishmaniasis >20 years ago. F) Heat map shows the correlation (pink: positive correlation; blue: negative correlation; white: no correlation) of epidemiological, virological and immunological characteristics of PWH.

This finding, together with the decreased CD4⁺ T cell counts found in our previous analysis (Table 2), corroborates the hypothesis that therapy-naïve HIV-1-infected subjects previously or currently infected with *L. infantum* exhibit a more intensified state of immune activation than HIV-1 positive, *L. infantum* seronegative subjects. During clinical follow-up, the introduction of antiretroviral therapy restored CD4⁺ T cell counts (median values of CD4⁺ T cell counts after 4-5 years of follow-up: DP=620 cells/μL and DN_{paired}=870 cells/μL) and reduced viral load levels to undetectable limits similarly in each group (Figure 5), with no statistically significant differences between groups (AUC comparison, data not shown).



384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

Figure 5. Long-term follow-up of CD4+, CD8+, CD4/CD8 ratio, CD45+ and viral load levels after therapy introduction in DP and DN_{paired} groups. A-J) Box plots with line plot overlays connecting medians of CD4+, CD8+, CD4/CD8 ratio, CD45+ and viral load levels during follow-up. A and F) Follow-up of viral load (copies/mL) in DN_{paired} (A) and DP (F) groups. B and G) Follow-up of CD4⁺ T cell count (cells/μL) in DN_{paired} (B) and DP (G) groups. C and H) Follow-up of CD8⁺ T cell count (cells/μL) in DN_{paired} (C) and DP (H) groups. D and I) Follow-up of CD4/CD8 (ratio) in DN_{paired} (D) and DP (I) groups. E and J) Follow-up of CD45⁺ T cell count (cells/μL) in DN_{paired} (E) and DP (J) groups. CXCL10 is shared between the HIV and visceral leishmaniasis gene signatures, while CXCL10, CXCL9 and CCL2 positively correlate with HIV viral load in untreated **PWH** Given the small number of immune activation markers and modest cohort size for the paired DP and DN groups, we aimed to validate and extend our findings by crossexamining independent cohorts of HIV-1 (Swiss HIV Cohort, n=137) or Leishmaniainfected individuals with and without active disease (Piaui Northeast Brazil, n=30) with publicly available transcriptome-wide data [40,41]. As shown in Figure 6A-B, a significant overlap (41 genes, enrichment p<0.0001) was found between the HIV and visceral leishmaniasis gene signatures when comparing the top 500 transcripts significantly upregulated during active disease in both untreated HIV patients and untreated visceral leishmaniasis patients, as compared to their paired post-treatment groups. A systems biology analysis of the 41 genes shared by HIV and leishmaniasis active disease signatures revealed several significantly enriched biological processes. encompassing immune activation broadly and, more specifically, type I IFN signaling and antiviral response. The overlapping genes included CXCL10, which we found to be

overexpressed in the DP group of our prospective cohort, as well as *STAT1*, the major transcription factor activated by IFN signaling. As detailed in Figure 6A and Supplementary Tables 3-5, enriched gene sets from Molecular Signatures Database (MSigDb) representing 'immune activation' included graft-versus-host disease, antigen recognition and blister cytotoxicity, while enriched gene sets representing 'type I IFN/antiviral response' comprised those upregulated in the liver by HBV infection, by IFN-alpha treatment of fibroblasts *in vitro* and by IFN-beta treatment of multiple sclerosis patients *in vivo*. Of interest, *IFNG* transcripts significantly decrease in monoinfected visceral leishmaniasis individuals, confirming our previous results obtained at the protein level for systemic IFN-γ in two independent VL cohorts [46,49].

perpetuity.
It is made available under a CC-BY 4.0 International license .




Figure 6. CXCL10 is shared between the HIV and visceral leishmaniasis disease signatures while *CXCL10*, *CXCL9* and *CCL2* transcripts positively correlate with HIV viral load in untreated PWH. Venn diagrams show overlap between (A) active disease gene signatures, i.e. genes upregulated in untreated PWH (Swiss cohorts) and visceral leishmaniasis patients (as compared to post-treatment) and (B) genes upregulated

419

420

421

422

423

424

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

in untreated PWH and asymptomatic Leishmania-infected individuals (who did not develop disease). Systems biology analysis shows a significant enrichment of gene sets comprising immune activation and type I IFN signaling (right-hand panels). (C) Selective up-regulation of CXCL10 and STAT1 (as a positive control for IFN signaling) transcripts in both untreated visceral leishmaniasis patients (upper panel) and *Leishmania infantum*exposed individuals (D) Selective up-regulation (upper panel) and positive correlation to viral load (lower panel) of CXCL10, CXCL9 and CCL2 and STAT1 (as a positive control for IFN signaling) transcripts in untreated PWH (Swiss cohort, n=137). To define a specific 'Leishmania infection' gene signature, we used the top 500 significantly upregulated transcripts from Leishmania-infected individuals who did not develop disease, for which *Leishmania* infection was documented by a positive skin DTH reaction, as compared to matched DTH-negative individuals from the same endemic area [41]. Surprisingly, the overlap between the 'untreated HIV' and 'Leishmania-seropositive (DP)' gene signatures was even more pronounced than the overlap between the 'untreated HIV' and 'untreated visceral leishmaniasis' gene signatures, both by quantitative (65 shared genes, Figure 6B) and qualitative measures (median gene set overlap 9.4% vs 3.2%, Mann-Whitney p<0.0001, Supplementary Table 3), indicating that even asymptomatic Leishmania infection has a profound effect on the systemic immune response. Again, CXCL10 and STAT1 were shared among the two disease signatures (Figure 6B), and enriched gene sets included type I IFN signaling (genes upregulated by IFN-beta treatment of multiple sclerosis patients in vivo and by IFN-alpha treatment of fibroblasts in vitro) and immune activation (inflammatory response to LPS, TNF signaling).

Validation of our DP cohort results revealed that *CXCL10*, but not *CCL2*, *CCL5* or *CXCL8* transcripts, were significantly upregulated by *Leishmania infantum* infection with or without clinically definite visceral leishmaniasis (Figure 6C upper and lower panel). In the Swiss HIV Cohort, we found that *CXCL10*, *CCL2* and, to a lesser extent, *CXCL9* transcripts were significantly upregulated during untreated HIV-1 infection. In contrast, no significant effect was observed for *CXCL8* in either asymptomatic or symptomatic *Leishmania infantum* infection, supporting our negative findings for *CXCL8* genetic variation in visceral leishmaniasis patients from the same endemic region [47]. However, *CXCL8* transcripts were significantly downregulated during untreated HIV-1 infection (Figure 6D upper panel). Finally, as shown in Figure 6D (lower panel), *CCL2*, *CXCL9* and *CXCL10* transcripts were significantly correlated (even after stringent correction for genome-wide testing) with set point viral load in untreated PWH from the Swiss HIV Cohort (n=137), confirming the results from our prospective cross-sectional cohort (Figure 4F).

DISCUSSION

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

The geographic overlap of HIV-1 and L. infantum infections raises the possibility of coinfection, which several groups have shown to increase morbidity and mortality [7,11,52– 58,13,14,19,21–23,50,51]. Several groups have studied the extent of this overlap in several Brazilian regions. However, no studies have attempted to determine the seroprevalence of L. infantum among PWH in the state of Bahia, despite the significant prevalence of both infections [25,26]. We used a two-stage cross-sectional cohort approach (CSC-I, n=5,346 and CSC-II, n=317) and identified positive serology for L. infantum ranging from 4.73% (DP for anti-SLA and anti-HSP70) to 18.93% in the CSC-II (union of all positive samples for anti-SLA and anti-HSP70), with an intermediate seroprevalence for only anti-SLA of 16.27% in the CSC-I and 15.46% in the CSC-II. The observed frequencies of *Leishmania* seroprevalence in PWH using any of the serology strategies in both the cross-sectional cohorts support previous findings falling within the range of what has already been described in other Brazilian regions [9,12,20,59]. Moreover, demographic data indicated that all DP patients were born in the macroregions surrounding the cities of Salvador and Feira de Santana, which are responsible for 33.8% (1,074/3,172) of notified VL cases in Bahia between 2007 and 2015 [25]. The observed discrepancy between the results obtained with the two different immunoassays might be explained by the rigor employed to determine cutoffs for each serological test and the imbalance in protein fractions between these two antigen-based diagnostic methods. SLA is a heterogeneous mix of antigens and has a lower concentration of HSP70 than parasite structural proteins (actin, tubulin, etc.). Even though it will pick up a broader set of samples, some samples with low antibody levels will fail. On the other hand, the recombinant HSP70 antigen is homogenous and highly

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

concentrated and has a better detection limit. We considered only those samples demonstrating dual positivity to increase confidence regarding past or present L. infantum infection. This strategy was underscored by the identification of one individual with a previous history of VL in the DP group and no cases with an earlier history of VL in the DN_{paired} group. Unfortunately, only serum or plasma samples were available for HIV-1 RNA extraction, thus precluding DNA analysis to detect L. infantum by qPCR, which we acknowledge as a limitation of our study. However, Fukutani et al. (2014) [60] demonstrated a concordance of 68% between anti-SLA serology and PCR, and found a 5.40% rate of ongoing asymptomatic L. infantum infection among blood donors in Salvador, Bahia. Nevertheless, positive IgG serology for L. infantum indicates immunological memory of at least a previous Leishmania infection before HIV diagnosis. Strikingly, we identified a DP individual with a pronounced humoral response two decades after a VL clinical diagnosis. This ongoing humoral response most likely reflects chronic antigen exposure, emphasizing the concept that *Leishmania* infection is lifelong in most patients, as well as murine models of disease [43-45]. A wealth of studies worldwide [14,42,61-64] and a recent systematic review [56] have demonstrated a high frequency of relapse of VL in PWH, as well as increased mortality. Relapse of VL have been reported after antileishmaniasis treatment, even years after the patient was considered clinically cured, especially in PWH and/or immunosuppressive conditions [13,51]. Prior large studies, including from our group, have found striking differences in the prevalence of VL within different regions in Brazil, as well as Southern Europe. The highest seroprevalence was observed in Mato Grosso, 41.40% of blood donors, in contrast

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

to other regions in Brazil (Salvador: 5.40% of 700 [60]; Paraná: 11.40% of 176 [65]; Fortaleza: 17.10% of 431 [66]), and in Southern Europe (France: 13.40% of 565 [67]; Spain: 3.10% of 1,437 [68]). Studies conducted in populations of newly diagnosed HIV-1-infected individuals from regions endemic for leishmaniasis in Brazil reported a prevalence of HIV-1/L. infantum co-infection ranging from 4.20% to 20.20%. In these studies, L. infantum infection was determined by parasitological, serological and/or molecular testing [9,12,20,59]. However, in co-infection studies focused on VL patients, which were diagnosed by parasitological, molecular or immunofluorescence methods, the prevalence of HIV-1/L. infantum coinfection ranged from 36.60% to 55.60% [16–18]. The present study also investigated possible differences in the prevalence of HIV-1 variants associated with L. infantum infection in PWH. With these subtyping results, we would like to investigate if a possible worsen disease progression in PWH with positive serology for L. infantum cases was related to cluster of transmission of a more-aggressive HIV subtype (e.g. HIV Subtype D) [69]. However, no differences were found concerning HIV-1 isolates between matched samples of patients infected (DP) or not (DN_{paired}) to L. infantum. Within these isolates, subtype B (63.16%) was found to be the most prevalent, followed by C (15.79%), recombinant BF (15.79%) and D (5.26%). Recent studies in Bahia that evaluated HIV-1 variant distribution have described the wide distribution of subtype B, followed by a smaller proportion of recombinant BF units [70–72]. Of note, the higher prevalence of subtype C (15.79%) found herein stands in contrast to other studies also conducted in this region, which reported a very low prevalence ranging from 1.70% to 2.50% [71,73,74].

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

Moreover, our confirmation of the circulation of subtype D in the state is following work by Monteiro et al. (2009) [75], who previously reported the presence of subtype D in individuals from Feira de Santana (0.60% of pol F/envD subtype), a city located ~100 km from Salvador. It is worth noting that the subtyping analysis performed herein involved three different methodologies (REGA HIV-1 Subtyping Tool, phylogeny and jpHMM-HIV probabilistic modeling), which lends support to the presently reported distribution. Furthermore, our subtype identification was performed using HIV-1 pol sequences, inferring subtype frequencies can vary when complete genome sequencing is performed. Prior research into host immune responses has demonstrated that L. infantum infection induces a higher level of immune activation in co-infected PWH, which could lead to a more rapid progression to AIDS [3,76–78]. Our study found a roughly five-fold increase in circulating CXCL10/IP-10 and CXCL9/MIG chemokines in PWH exposed to L. infantum, supporting a link between positive serology for L. infantum and immune activation, which we validated at the transcript level for CXCL10 in independent HIV-1 and Leishmania-infected cohorts. These chemokines are strongly induced by both type I (IFN- α/β) and type II IFN (IFN- γ) [79–82]. It has been previously reported that Th1 subpopulations of CD4⁺CD95⁺ T cells in HIV-1 infected individuals are highly susceptible to HIV-1 envelope gp120-induced apoptosis [83,84], which may corroborate the deleterious role of intensified immune activation [85–87]. In a submitted manuscript (Khouri et al.), we demonstrated an increase in both systemic soluble Fas as well as membrane-bound Fas/CD95 expression in CD8+ cells in HIV/VL co-infection, as compared to HIV-1 or VL mono-infected groups, in a large cohort of individuals recruited during an outbreak of VL in Piaui, another state in the same northeast region of Brazil.

Since we previously demonstrated STAT1-mediated IFN signaling as a preferential inducer of Fas/CD95 at both the protein and transcript level [88,89], this study as well as Khouri *et al.* (submitted) underscore the pivotal role of IFN-driven immune activation in HIV-1 and *Leishmania infantum* co-infection and its deleterious effect on both AIDS progression and visceral leishmaniasis.

The present study aimed to describe the prevalence and consequences of *L. infantum* infection in a population of antiretroviral treatment-naïve PWH at diagnosis. We found a high seroprevalence of *L. infantum* in treatment-naïve PWH in Bahia (Brazil) associated with a more intensified state of immune activation as compared to HIV-1 monoinfected subjects, possibly exacerbating progression to AIDS, which was observed in 66.67% in co-infected individuals at diagnosis. Moreover, *Leishmania*-infected PWH are at high risk of developing severe visceral leishmaniasis [56]. These findings underscore the urgent need to increase awareness and define public health strategies for the management and prevention of HIV-1 and *L. infantum* co-infection.

580

581

582

583

584

585

586

587

588

FUNDING This work was financed in part by Fundação de Amparo à Pesquisa do Estado da Bahia (FAPESB, APP0032/2016), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES – finance code 001) and FWO (grant G0D6817N). None of the funding organizations had any role in the study design, data collection, data interpretation or writing of this report. ACKNOWLEDGMENTS The authors would like to thank Andris K. Walter for English language revision and manuscript copyediting assistance.

REFERENCES

589

- 590 1. Costin JM. Cytopathic Mechanisms of HIV-1. Virol J. 2007;4: 100.
- 591 doi:10.1186/1743-422X-4-100
- 592 2. Perkins MR, Bartha I, Timmer JK, Liebner JC, Wollinsky D, Günthard HF, et al.
- 593 The Interplay Between Host Genetic Variation, Viral Replication, and Microbial
- 594 Translocation in Untreated HIV-Infected Individuals, J Infect Dis. 2015;212: 578–
- 595 584. doi:10.1093/infdis/jiv089
- 596 Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, et al. 3.
- 597 Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral
- 598 load in memory CD4 + T cells, and disease progression. Proc Natl Acad Sci.
- 599 2015;112: E1480–E1489. doi:10.1073/pnas.1421607112
- 600 Kouri V, Khouri R, Alemán Y, Abrahantes Y, Vercauteren J, Pineda-Peña A-C, et 4.
- 601 al. CRF19 cpx is an Evolutionary fit HIV-1 Variant Strongly Associated With
- 602 Rapid Progression to AIDS in Cuba. EBioMedicine. 2015;2: 244–254.
- 603 doi:10.1016/j.ebiom.2015.01.015
- 604 van Griensven J, Ritmeijer K, Lynen L, Diro E. Visceral Leishmaniasis as an AIDS 5.
- 605 Defining Condition: Towards Consistency across WHO Guidelines. Ghedin E,
- 606 editor, PLoS Negl Trop Dis. 2014;8: e2916. doi:10.1371/journal.pntd.0002916
- 607 World Health Organization. Investing To Overcome the Global Impact of 6.
- 608 Neglected Tropical Diseases: third WHO Report on Neglected Tropical Diseases.
- 609 2015.
- 610 7. Coura-Vital W, Araújo VEM de, Reis IA, Amancio FF, Reis AB, Carneiro M.
- 611 Prognostic Factors and Scoring System for Death from Visceral Leishmaniasis: An
- 612 Historical Cohort Study in Brazil. Santiago H da C, editor. PLoS Negl Trop Dis.
- 613 2014;8: e3374. doi:10.1371/journal.pntd.0003374

- 8. Leite de Sousa-Gomes M, Nilce Silveira Maia-Elkhoury A, Maria Pelissari D,
- Edilson Ferreira de Lima Junior F, Martins de Sena J, Paula Cechinel M.
- 616 Coinfecção Leishmania-HIV no Brasil: aspectos epidemiológicos, clínicos e
- 617 laboratoriais. Epidemiol e Serviços Saúde. 2011;20: 519–526. doi:10.5123/S1679-
- 618 49742011000400011
- 619 9. Carranza-Tamayo CO, Assis TSM de, Neri ATB, Cupolillo E, Rabello A, Romero
- GAS. Prevalence of Leishmania infection in adult HIV/AIDS patients treated in a
- 621 tertiary-level care center in Brasilia, Federal District, Brazil. Trans R Soc Trop
- Med Hyg. 2009;103: 743–748. doi:10.1016/j.trstmh.2009.01.014
- 623 10. Távora LGF, Nogueira MB, Gomes ST. Visceral Leishmaniasis/HIV co-infection
- in northeast Brazil: evaluation of outcome. Brazilian J Infect Dis. 2015;19: 651–
- 625 656. doi:10.1016/j.bjid.2015.07.004
- 626 11. Diniz LFB, de Souza CDF, do Carmo RF. Epidemiology of human visceral
- leishmaniasis in the urban centers of the lower-middle São Francisco Valley,
- Brazilian semiarid region. Rev Soc Bras Med Trop. 2018;51: 461–466.
- doi:10.1590/0037-8682-0074-2018
- 630 12. Carvalho FL, Aires DLS, Segunda ZF, Azevedo CMPES De, Corrêa RDGCF,
- Aquino DMC de, et al. Perfil epidemiológico dos indivíduos HIV positivo e
- coinfeção HIV-Leishmania em um serviço de referência em São Luís, MA, Brasil.
- 633 Cien Saude Colet. 2013;18: 1305–1312. doi:10.1590/S1413-81232013000500015
- 634 13. Silva de Lima UR, Vanolli L, Moraes EC, Ithamar JS, Pedrozo e Silva de Azevedo
- C de M. Visceral leishmaniasis in Northeast Brazil: What is the impact of HIV on
- 636 this protozoan infection? PLoS One. 2019;14: 1–14.
- 637 doi:10.1371/journal.pone.0225875
- 638 14. Luz JGG, Naves DB, de Carvalho AG, Meira GA, Dias JVL, Fontes CJF. Visceral

- leishmaniasis in a Brazilian endemic area: An overview of occurrence, HIV
- coinfection and lethality. Rev Inst Med Trop Sao Paulo. 2018;60: 1–9.
- doi:10.1590/S1678-9946201860012
- 642 15. Botelho ACA, Natal D. Primeira descrição epidemiológica da leishmaniose
- visceral em Campo Grande, Estado de Mato Grosso do Sul. Rev Soc Bras Med
- Trop. 2009;42: 503–508. doi:10.1590/S0037-86822009000500006
- 16. Druzian AF, Souza AS de, Campos DN de, Croda J, Higa MG, Dorval MEC, et al.
- Risk Factors for Death from Visceral Leishmaniasis in an Urban Area of Brazil.
- PLoS Negl Trop Dis. 2015;9: e0003982. doi:10.1371/journal.pntd.0003982
- 648 17. Cota GF, de Sousa MR, de Mendonça ALP, Patrocinio A, Assunção LS, de Faria
- SR, et al. Leishmania-HIV Co-infection: Clinical Presentation and Outcomes in an
- Urban Area in Brazil. Debrabant A, editor. PLoS Negl Trop Dis. 2014;8: e2816.
- doi:10.1371/journal.pntd.0002816
- 652 18. Souza GF de, Biscione F, Greco DB, Rabello A. Slow clinical improvement after
- treatment initiation in Leishmania/HIV coinfected patients. Rev Soc Bras Med
- Trop. 2012;45: 147–150. doi:10.1590/S0037-86822012000200001
- 655 19. Sousa JM dos S, Ramalho WM, De Melo MA. Demographic and clinical
- characterization of human visceral leishmaniasis in the State of Pernambuco,
- Brazil between 2006 and 2015. Rev Soc Bras Med Trop. 2018;51: 622–630.
- doi:10.1590/0037-8682-0047-2018
- 659 20. Soares VYR, Lúcio Filho CEP, Carvalho LIM de, Silva AMM de M e, Eulálio KD.
- 660 Clinical and epidemiological analysis of patients with HIV/AIDS admitted to a
- reference hospital in the northeast region of Brazil. Rev Inst Med Trop Sao Paulo.
- 662 2008;50: 327–332. doi:10.1590/S0036-46652008000600003
- 663 21. Lima ÁLM, de Lima ID, Coutinho JFV, de Sousa ÚPST, Rodrigues MAG, Wilson

perpetuity.

It is made available under a CC-BY 4.0 International license .

- ME, et al. Changing epidemiology of visceral leishmaniasis in northeastern Brazil:
- A 25-year follow-up of an urban outbreak. Trans R Soc Trop Med Hyg. 2017;111:
- 666 440–447. doi:10.1093/trstmh/trx080
- Lima ID, Lima ALM, Mendes-Aguiar C de O, Coutinho JFV, Wilson ME, Pearson
- RD, et al. Changing demographics of visceral leishmaniasis in northeast Brazil:
- Lessons for the future. PLoS Negl Trop Dis. 2018;12: 1–16.
- doi:10.1371/journal.pntd.0006164
- 671 23. Santos GDO, De Jesus NPS, Cerqueira-Braz JV, Santos VS, De Lemos LMD.
- Prevalence of HIV and associated factors among visceral leishmaniasis cases in an
- endemic area of Northeast Brazil. Rev Soc Bras Med Trop. 2019;52: 1–4.
- doi:10.1590/0037-8682-0257-2018
- 675 24. Albuquerque LCP de, Mendonça IR, Cardoso PN, Baldaçara LR, Borges MRMM,
- Borges J da C, et al. HIV/AIDS-related visceral leishmaniasis: a clinical and
- epidemiological description of visceral leishmaniasis in northern Brazil. Rev Soc
- 678 Bras Med Trop. 2014;47: 38–46. doi:10.1590/0037-8682-0180-2013
- 679 25. Secretaria de Saúde do Estado da Bahia. Informe Epidemiológico de Leishmaniose
- 680 Visceral, Bahia. 2018.
- 681 26. Secretaria Municipal de Saúde de Salvador. Boletim Epidemiológico de AIDS:
- 682 Situação Epidemiológica da AIDS em Salvador, Bahia. 2019.
- 683 27. Charlab R, Barral-Netto M, Valenzuela JG, Barral A, Caldas A, Honda E, et al.
- Human immune response to sand fly salivary gland antigens: a useful
- epidemiological marker? Am J Trop Med Hyg. 2000;62: 740–745.
- doi:10.4269/ajtmh.2000.62.740
- 687 28. Souza AP, Soto M, Costa JML, Boaventura VS, de Oliveira CI, Cristal JR, et al.
- Towards a More Precise Serological Diagnosis of Human Tegumentary

- Leishmaniasis Using Leishmania Recombinant Proteins. Zamboni DS, editor.
- 690 PLoS One. 2013;8: e66110. doi:10.1371/journal.pone.0066110
- 691 29. Soto M, Corvo L, Garde E, Ramírez L, Iniesta V, Bonay P, et al. Coadministration
- of the Three Antigenic Leishmania infantum Poly (A) Binding Proteins as a DNA
- Vaccine Induces Protection against Leishmania major Infection in BALB/c Mice.
- 694 Melby PC, editor. PLoS Negl Trop Dis. 2015;9: e0003751.
- 695 doi:10.1371/journal.pntd.0003751
- 696 30. Barreto CC, Nishyia A, Araújo L V., Ferreira JE, Busch MP, Sabino EC. Trends
- in antiretroviral drug resistance and clade distributions among HIV-1-infected
- 698 blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr. 2006;41: 338–
- 699 341. doi:10.1097/01.qai.0000199097.88344.50
- 700 31. Kozal MJ, Shah N, Shen N, Yang R, Fucini R, Merigan TC, et al. Extensive
- polymorphisms observed in HIV-1 clade B protease gene using high-density
- 702 oligonucleotide arrays. Nat Med. 1996;2: 753–759. doi:10.1038/nm0796-753
- 703 32. Pieniazek D, Peralta JM, Ferreira JA, Krebs JW, Owen SM, Sion FS, et al.
- Identification of mixed HIV-1/HIV-2 infections in Brazil by polymerase chain
- reaction. AIDS. 1991;5: 1293–1300. doi:10.1097/00002030-199111000-00002
- 706 33. Frenkel LM, Wagner LE, Atwood SM, Cummins TJ, Dewhurst S. Specific,
- sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations
- associated with resistance to zidovudine and didanosine. J Clin Microbiol.
- 709 1995;33: 342–347. doi:10.1128/jcm.33.2.342-347.1995
- 710 34. Janini LM, Pieniazek D, Peralta JM, Schechter M, Tanuri A, Vicente ACP, et al.
- 711 Identification of single and dual infections with distinct subtypes of human
- immunodeficiency virus type 1 by using restriction fragment length polymorphism
- 713 analysis. Virus Genes. 1996;13: 69–81. doi:10.1007/BF00576981

- 714 35. Schultz A-K, Zhang M, Bulla I, Leitner T, Korber B, Morgenstern B, et al.
- 715 jpHMM: Improving the reliability of recombination prediction in HIV-1. Nucleic
- 716 Acids Res. 2009;37: W647–W651. doi:10.1093/nar/gkp371
- 717 36. Guindon S, Dufayard J-F, Lefort V, Anisimova M, Hordijk W, Gascuel O. New
- 718 Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies:
- Assessing the Performance of PhyML 3.0. Syst Biol. 2010;59: 307–321.
- 720 doi:10.1093/sysbio/syq010
- 721 37. Vivarini áislan de C, Calegari-Silva TC, Saliba AM, Boaventura VS, França-Costa
- J, Khouri R, et al. Systems Approach Reveals Nuclear Factor Erythroid 2-Related
- Factor 2/Protein Kinase R Crosstalk in Human Cutaneous Leishmaniasis. Front
- 724 Immunol. 2017;8: 1–18. doi:10.3389/fimmu.2017.01127
- 725 38. Subramanian K, Dierckx T, Khouri R, Menezes SM, Kagdi H, Taylor GP, et al.
- Decreased RORC expression and downstream signaling in HTLV-1-associated
- adult T-cell lymphoma/leukemia uncovers an antiproliferative IL17 link: A
- potential target for immunotherapy? Int J Cancer. 2019;144: 1664–1675.
- 729 doi:10.1002/ijc.31922
- 730 39. Delgobo M, Mendes DAGB, Kozlova E, Rocha EL, Rodrigues-Luiz GF, Mascarin
- L, et al. An evolutionary recent IFN/IL-6/CEBP axis is linked to monocyte
- expansion and tuberculosis severity in humans. Elife. 2019;8: 1–32.
- 733 doi:10.7554/eLife.47013
- 734 40. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, et al. Genome-
- 735 Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-
- 1-Infected Individuals. Emerman M, editor. PLoS Pathog. 2010;6: e1000781.
- 737 doi:10.1371/journal.ppat.1000781
- 738 41. Gardinassi LG, Garcia GR, Costa CHN, Costa Silva V, de Miranda Santos IKF.

- perpetuity.

 It is made available under a CC-BY 4.0 International license .
- 739 Blood Transcriptional Profiling Reveals Immunological Signatures of Distinct
- States of Infection of Humans with Leishmania infantum. Acosta-Serrano A,
- 741 editor. PLoS Negl Trop Dis. 2016;10: e0005123.
- 742 doi:10.1371/journal.pntd.0005123
- 743 42. Zacarias DA, Rolão N, de Pinho FA, Sene I, Silva JC, Pereira TC, et al. Causes
- and consequences of higher Leishmania infantum burden in patients with kala-
- 745 azar: a study of 625 patients. Trop Med Int Heal. 2017;22: 679–687.
- 746 doi:10.1111/tmi.12877
- 747 43. Bogdan C, Donhauser N, Döring R, Röllinghoff M, Diefenbach A, Rittig MG.
- Fibroblasts as host cells in latent leishmaniosis. J Exp Med. 2000;191: 2121–2129.
- 749 doi:10.1084/jem.191.12.2121
- 750 44. Paduch K, Debus A, Rai B, Schleicher U, Bogdan C. Resolution of Cutaneous
- Leishmaniasis and Persistence of Leishmania major in the Absence of Arginase 1
- 752 . J Immunol. 2019;202: 1453–1464. doi:10.4049/jimmunol.1801249
- 753 45. Seved N, Peters NC, Rafati S. Translating observations from Leishmanization into
- non-living vaccines: The potential of dendritic cell-based vaccination strategies
- 755 against Leishmania. Front Immunol. 2018;9: 1–10.
- 756 doi:10.3389/fimmu.2018.01227
- 757 46. Caldas A, Favali C, Aquino D, Vinhas V, van Weyenbergh J, Brodskyn C, et al.
- 758 Balance of IL-10 and interferon-γ plasma levels in human visceral leishmaniasis:
- 759 Implications in the pathogenesis. BMC Infect Dis. 2005;5: 1–9. doi:10.1186/1471-
- 760 2334-5-113
- 761 47. Frade AF, Oliveira LC de, Costa DL, Costa CHN, Aquino D, Van Wevenbergh J,
- et al. TGFB1 and IL8 gene polymorphisms and susceptibility to visceral
- 763 leishmaniasis. Infect Genet Evol. 2011:11: 912–916.

- 764 doi:10.1016/j.meegid.2011.02.014
- 765 48. Carneiro MW, Fukutani KF, Andrade BB, Curvelo RP, Cristal JR, Carvalho AM,
- 766 et al. Gene Expression Profile of High IFN-y Producers Stimulated with
- 767 braziliensis Identifies Genes Associated Leishmania with Cutaneous
- 768 Leishmaniasis. McDowell MA, editor. PLoS Negl Trop Dis. 2016;10: e0005116.
- 769 doi:10.1371/journal.pntd.0005116
- 770 49. Peruhype-Magalhães V, Martins-Filho OA, Prata A, Silva LDA, Rabello A,
- 771 Teixeira-Carvalho A, et al. Mixed inflammatory/regulatory cytokine profile
- 772 marked by simultaneous raise of interferon-y and interleukin-10 and low frequency
- 773 of tumour necrosis factor-α+ monocytes are hallmarks of active human visceral
- 774 Leishmaniasis due to Leishmania chagasi infectio. Clin Exp Immunol. 2006;146:
- 775 124–132. doi:10.1111/j.1365-2249.2006.03171.x
- 776 50. Botana L, Ibarra-Meneses AV, Sánchez C, Castro A, Martin JVS, Molina L, et al.
- 777 Asymptomatic immune responders to Leishmania among HIV positive patients.
- 778 PLoS Negl Trop Dis. 2019;13: 1–14. doi:10.1371/journal.pntd.0007461
- 779 51. Horrillo L, Castro A, Matía B, Molina L, García-Martínez J, Jaqueti J, et al.
- 780 Clinical aspects of visceral leishmaniasis caused by L. infantum in adults. Ten
- 781 years of experience of the largest outbreak in Europe: what have we learned?
- 782 Parasit Vectors. 2019;12: 359. doi:10.1186/s13071-019-3628-z
- 783 Ana Nilce S M, Adolfo G, Romero S, Samantha YOB, Lindoso AL, Elisa C, et al. 52.
- 784 Premature deaths by visceral leishmaniasis in Brazil investigated through a cohort
- 785 study: A challenging opportunity? PLoS Negl Trop Dis. 2019;13: 1–18.
- 786 doi:https://doi.org/10.1371/journal.pntd.0007841
- 787 53. Van Griensven J, van Henten S, Mengesha B, Kassa M, Adem E, Seid ME, et al.
- 788 Longitudinal evaluation of asymptomatic Leishmania infection in HIV-infected

- 789 individuals in North-West Ethiopia: A pilot study. PLoS Negl Trop Dis. 2019;13:
- 790 30–45. doi:10.1371/journal.pntd.0007765
- 791 54. Diro E, Edwards T, Ritmeijer K, Fikre H, Abongomera C, Kibret A, et al. Long
- term outcomes and prognostics of visceral leishmaniasis in hiv infected patients
- with use of pentamidine as secondary prophylaxis based on CD4 level: A
- prospective cohort study in Ethiopia. PLoS Negl Trop Dis. 2019;13: 1–17.
- 795 doi:10.1371/journal.pntd.0007132
- 796 55. Prestes-Carneiro LE, Spir PRN, Fontanesi M, Pereira Garcia KG, Silva FA Da,
- Flores EF, et al. Unusual manifestations of visceral leishmaniasis in children: A
- case series and its spatial dispersion in the western region of São Paulo state,
- 799 Brazil. BMC Infect Dis. 2019;19: 1–9. doi:10.1186/s12879-018-3652-1
- 800 56. Fontoura IG, Barbosa DS, de Andrade Paes AM, Santos FS, Neto MS, Fontoura
- VM, et al. Epidemiological, clinical and laboratory aspects of human visceral
- leishmaniasis (HVL) associated with human immunodeficiency virus (HIV)
- 803 coinfection: a systematic review CORRIGENDUM. Parasitology. 2018;145:
- 804 1819–1819. doi:10.1017/S0031182018001166
- 805 57. Rezaei Z, Sarkari B, Dehghani M, Layegh Gigloo A, Afrashteh M. High frequency
- of subclinical Leishmania infection among HIV-infected patients living in the
- 807 endemic areas of visceral leishmaniasis in Fars province, southern Iran. Parasitol
- 808 Res. 2018;117: 2591–2595. doi:10.1007/s00436-018-5949-9
- 809 58. Viana GM de C, da Silva MACN, Garcia JV de S, Guimarães HD, Arcos Júnior
- GF, Santos AVA, et al. Epidemiological profile of patients co-infected with
- visceral leishmaniasis and HIV/AIDS in northeast, Brazil. Rev Soc Bras Med Trop.
- 812 2017;50: 613–620. doi:10.1590/0037-8682-0494-2017
- 813 59. Orsini M, Canela JR, Disch J, Maciel F, Greco D, Toledo A, et al. High frequency

814 of asymptomatic Leishmania spp. infection among HIV-infected patients living in 815 endemic areas for visceral leishmaniasis in Brazil. Trans R Soc Trop Med Hvg. 816 2012;106: 283–288. doi:10.1016/j.trstmh.2012.01.008 817 Fukutani KF, Figueiredo V, Celes FS, Cristal JR, Barral A, Barral-Netto M, et al. 60. 818 Serological survey of Leishmaniainfection in blood donors in Salvador, 819 Northeastern Brazil. BMC Infect Dis. 2014;14: 422. doi:10.1186/1471-2334-14-820 422 821 61. Oryan A, Akbari M. Worldwide risk factors in leishmaniasis. Asian Pac J Trop 822 Med. 2016;9: 925–932. doi:10.1016/j.apjtm.2016.06.021 823 62. Grande E, Zucchetto A, Suligoi B, Grippo F, Pappagallo M, Virdone S, et al. 824 Multiple cause-of-death data among people with AIDS in Italy: A nationwide cross-sectional study. Popul Health Metr. 2017;15: 1-12. doi:10.1186/s12963-825 826 017-0135-3 827 Bruhn FRP, Morais MHF, Bruhn NCP, Cardoso DL, Ferreira F, Rocha CMBM. 63. 828 Human visceral leishmaniasis: Factors associated with deaths in Belo Horizonte, 829 Minas Gerais state, Brazil from 2006 to 2013. Epidemiol Infect. 2018;146: 565-830 570. doi:10.1017/S0950268818000109 831 64. Guedes DL, Medeiros Z, Da Silva ED, De Vasconcelos AVM, Da Silva MS, Da 832 Silva MAL, et al. Visceral leishmaniasis in hospitalized HIV-infected patients in 833 Pernambuco. Brazil. Am J Trop Med Hyg. 2018;99: 1541–1546. 834 doi:10.4269/ajtmh.17-0787 835 65. Braga L de S, Navasconi TR, Leatte EP, Skraba CM, Silveira TGV, Ribas-Silva 836 RC. Presence of anti-leishmania (viannia) braziliensis antibodies in blood donors 837 in the west-central region of the state of Paraná, Brazil. Rev Soc Bras Med Trop. 838 2015;48: 622-625. doi:10.1590/0037-8682-0043-2015

- 839 Monteiro DCS, Sousa AO, Lima DM, Fontes RM, Praciano CC, Frutuoso MS, et 66.
- 840 al. Leishmania infantum Infection in Blood Donors, Northeastern Brazil. Emerg
- 841 Infect Dis. 2016;22: 739–740. doi:10.3201/eid2204.150065
- 842 le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, Suffia I, et al. 67.
- 843 Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors
- 844 living in an area of endemicity in southern France. J Clin Microbiol. 1999:37:
- 845 1953–7.
- 846 de Oliveira França A, Pompilio MA, Pontes ERJC, de Oliveira MP, Pereira LOR, 68.
- 847 Lima RB, et al. Leishmania infection in blood donors: A new challenge in
- 848 leishmaniasis transmission? **PLoS** One. 2018;13: 1-13.
- 849 doi:10.1371/journal.pone.0198199
- 850 Khouri R, Vandamme AM. Virus genetic variability involvement in 69.
- 851 transmissibility of HIV-1 immune activation and disease progression. Future Virol.
- 852 2015;10: 1259-1262. doi:10.2217/fvl.15.96
- 853 70. Araujo AF, Brites C, Monteiro-Cunha J, Santos LA, Galvao-Castro B, Alcantara
- 854 LCJ. Lower Prevalence of Human Immunodeficiency Virus Type 1 Brazilian
- 855 Subtype B Found in Northeastern Brazil with Slower Progression to AIDS. AIDS
- 856 Res Hum Retroviruses. 2010;26: 1249–1254. doi:10.1089/aid.2010.0068
- 857 71. Monteiro-Cunha JP, Araujo AF, Santos E, Galvao-Castro B, Alcantara LCJ. Lack
- 858 of High-Level Resistance Mutations in HIV Type 1 BF Recombinant Strains
- 859 Circulating in Northeast Brazil. AIDS Res Hum Retroviruses. 2011;27: 623–631.
- 860 doi:10.1089/aid.2010.0126
- 861 72. Santos LA, Monteiro-Cunha JP, Araújo AF, Brites C, Galvão-Castro B, Alcantara
- 862 LCJ. Detection of Distinct Human Immunodeficiency Virus Type 1 Circulating
- Recombinant Forms in Northeast Brazil. J Med Virol. 2011;83: 2066-2072. 863

- 864 doi:10.1002/jmv
- 865 73. Chavez HH, Tran T-A, Dembele B, Nasreddine N, Lambotte O, Gubler B, et al.
- 866 Lack of Evidence for Prolonged Double-Long Terminal Repeat Episomal HIV
- 867 DNA Stability In Vivo. JAIDS J Acquir Immune Defic Syndr. 2007;45: 247–249.
- 868 doi:10.1097/QAI.0b013e3180415dc2
- 869 Santos EDS, Araújo AF, Galvão-Castro B, Alcantara LCJ. Diversidade genética 74.
- 870 do vírus da imunodeficiência humana tipo 1 (HIV-1) em mulheres infectadas de
- 871 uma cidade do nordeste do Brasil. Rev Bras Ginecol e Obs. 2009;31: 609-614.
- 872 doi:10.1590/S0100-72032009001200006
- 873 75. Monteiro JP, Alcantara LCJ, de Oliveira T, Oliveira AM, Melo MAG, Brites C, et
- 874 al. Genetic variability of human immunodeficiency virus-1 in Bahia state,
- Northeast, Brazil: High diversity of HIV genotypes. J Med Virol. 2009;81: 391-875
- 876 399. doi:10.1002/jmv.21414
- 877 Hoffmann M, Pantazis N, Martin GE, Hickling S, Hurst J, Meyerowitz J, et al. 76.
- 878 Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary
- 879 HIV-1 Infection. Wanstrom R, editor. PLOS Pathog. 2016;12: e1005661.
- 880 doi:10.1371/journal.ppat.1005661
- 881 77. Ipp H, Zemlin AE, Erasmus RT, Glashoff RH, Role of inflammation in HIV-1
- 882 disease progression and prognosis. Crit Rev Clin Lab Sci. 2014;51: 98-111.
- 883 doi:10.3109/10408363.2013.865702
- 884 Utay NS, Hunt PW. Role of immune activation in progression to AIDS. Curr Opin 78.
- 885 HIV AIDS. 2016;11: 131–137. doi:10.1097/COH.0000000000000242
- 886 Kedzierska K, Crowe SM. Cytokines and HIV-1: Interactions and Clinical 79.
- 887 Implications. Chem Chemother. 2001;12: 133–150. Antivir
- 888 doi:10.1177/095632020101200301

- 889 80. Kenway-Lynch CS, Das A, Lackner AA, Pahar B. Cytokine/Chemokine
- 890 Responses in Activated CD4+ and CD8+ T Cells Isolated from Peripheral Blood.
- 891 Axillary Lymph Marrow, and Nodes during Simian
- 892 Immunodeficiency Virus Infection. Virol. 2014;88: 9442-9457.
- 893 doi:10.1128/JVI.00774-14
- 894 81. Mehla R. Chemokine Deregulation in HIV Infection: Role of Interferon Gamma
- 895 Th1-Chemokine Signaling. J Clin Cell Immunol.
- 896 doi:10.4172/2155-9899.S7-004
- 897 Utay NS, Douek DC. Interferons and HIV Infection: The Good, the Bad, and the 82.
- 898 Ugly. Pathog Immun. 2016;1: 107. doi:10.20411/pai.v1i1.125
- 899 83. Accornero P, Radrizzani M, Delia D, Gerosa F, Kurrle R, Colombo MP.
- 900 Differential Susceptibility to HIV-GP120-Sensitized Apoptosis in CD4+ T-Cell
- 901 Clones With Different T-Helper Phenotypes: Role of CD95/CD95L Interactions.
- 902 Blood. 1997;89: 558-569. doi:10.1182/blood.V89.2.558
- 903 84. Cummins NW, Badley AD. Mechanisms of HIV-associated lymphocyte apoptosis:
- 904 2010. Cell Death Dis. 2010;1: e99–e99. doi:10.1038/cddis.2010.77
- 905 Costa ASA, Costa GC, Aquino DMC de, Mendonça VRR de, Barral A, Barral-85.
- 906 Netto M, et al. Cytokines and visceral leishmaniasis: a comparison of plasma
- 907 cytokine profiles between the clinical forms of visceral leishmaniasis. Mem Inst
- 908 Oswaldo Cruz. 2012;107: 735–739. doi:10.1590/S0074-02762012000600005
- 909 Rodrigues V, Cordeiro-da-Silva A, Laforge M, Silvestre R, Estaquier J. Regulation 86.
- 910 of immunity during visceral Leishmania infection. Parasit Vectors. 2016;9: 118.
- 911 doi:10.1186/s13071-016-1412-x
- 912 87. Sun H, Kim D, Li X, Kiselinova M, Ouyang Z, Vandekerckhove L, et al. Th1/17
- 913 Polarization of CD4 T Cells Supports HIV-1 Persistence during Antiretroviral

914 Therapy. Silvestri G, editor. J Virol. 2015;89: 11284-11293. 915 doi:10.1128/JVI.01595-15 916 88. Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D, Theys K, et al. 917 A genetic IFN/STAT1/FAS axis determines CD4 T stem cell memory levels and 918 apoptosis in healthy controls and Adult T-cell Leukemia patients. 919 Oncoimmunology. 2018;7: e1426423. doi:10.1080/2162402X.2018.1426423 920 Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, et al. 89. 921 Fas-670 promoter polymorphism is associated to susceptibility, clinical 922 presentation, and survival in adult T cell leukemia. J Leukoc Biol. 2008;83: 220-222. doi:10.1189/jlb.0407198 923

924




Figure 2 A

anti-SLA 1998-2013




Figure 2 B




Figure 1




Figure 3 A

anti-SLA 2014-2015




Figure 3 B

anti-HSP70 2014-2015




Figure 3 C




Figure 3 D




Figure 4 A




Figure 4 B




Figure 4 C




Figure 4 D




Figure 4 E





Figure 6 A

HIV untreated up Leishmania exposed






Figure 6 B

Leishmania active disease UP

Ge ped x eprint doi: https://doi.org/10.1101/2021 preprint (which was not certified by peer review	.10.0 <mark>3.2126/3311: versio</mark>	ted October 4, 2021. The ranted medRxiv a license t	copyright h of for the alue	FDR
CCL2	ailable under a 👀 BÝ 4.0 Internati	-0.14	0.15	0.47
CCL5		0.38	0.20	0.52
CXCL8		-0.16	0.06	0.32
CXCL9	ND		NA	NA
CXCL10		0.81	0.00003	0.0027
STAT1		1.18	0.00002	0.0024

Leishmania-exposed UP

Gene	logFC		p value	FDR
CCL2		0.04	0.21	0.89
CCL5		-0.11	0.39	0.95
CXCL8		-0.12	0.2	0.890
CXCL9		ND_	NA	NA
CXCL10		0.14	0.0089	0.59
STAT1		0.45	0.011	0.62
				_

Figure 6 C

HIV untreated UP

Gene medRxiv preprint doi: https://doi.org/10.1101/202	21.10.03.212643 is version posted October 4, 2021. The copy	p value	FDR
CCL2	perpetuity. vailable under a CC-BY 4.0 International license .	0.0019	0.10
CCL5	0.01	0.96	0.99
CXCL8	-0.60	0.0021	0.10
CXCL9	0.03	0.017	0.27
CXCL10	0.15	0.030	0.32
STAT1	0.15	0.030	0.32

Correlation HIV viral load set point

Gene	Spearman's R		p value	FDR
CCL2		0.31	0.00047	0.04
CCL5		0.16	0.076	0.29
CXCL8		-0.13	0.14	0.55
CXCL9		0.3	0.00052	0.08
CXCL10		0.43	6.23E-07	6.90E-04
STAT1		0.5	6.33E-09	3.82E-06
		_		

Figure 6 D




Figure 4 F




Figure 5 A




Figure 5 B




Figure 5 C




Figure 5 D




Figure 5 E




Figure 5 F




Figure 5 G




Figure 5 H




Figure 5 I




Figure 5 J